Compare American Airlines Group Inc (AAL) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs Amphastar Pharmaceuticals Inc — how do they compare? American Airlines Group Inc trades at $15.32 (market cap $10.55B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: American Airlines Group Inc is far larger — about 12.2× Amphastar Pharmaceuticals Inc's market cap, and American Airlines Group Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AAL | AMPH | |
|---|---|---|
Market Cap | $10.55B | $863.95M |
Sector | Industrials | Health |
52-Week High | $18.15 | $30.81 |
52-Week Low | $10.18 | $16.87 |
Enterprise Value | $38.51B | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAL trades at $15.94, down 0.56% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025. Revenue growth is steady, reaching $54.63 billion in 2025, though net income margins are thin at 0.2%. Debt-to-asset ratios have improved to 47.25% in 2025, but negative shareholder equity remains a concern. Recent news highlights advancements in sustainable aviation fuel and premium revenue growth.
The outlook is cautiously optimistic, supported by analyst consensus favoring buy ratings (44.74%) and a $19.63 price target, implying 23% upside. Key opportunities include robust premium demand and cost management, while risks involve fuel cost volatility, high debt, and competitive pressures. Earnings execution and fuel price trends will be critical for sustained stock performance.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
